3 drug(s) with this reaction
69 total reports
Application Site Vesicles has been reported as an adverse reaction across 3 drug(s) manufactured by Chattem Inc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 69 adverse event reports mention application site vesicles in connection with Chattem Inc products.
This page provides a breakdown of which Chattem Inc drugs are most commonly associated with application site vesicles, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.
The following Chattem Inc drugs have application site vesicles listed in their FDA adverse event reports, sorted by report count:
In addition to application site vesicles, the following adverse reactions have been reported across Chattem Inc's drug portfolio:
3 drug(s) manufactured by Chattem Inc have application site vesicles listed in their FDA adverse event reports: MENTHOL, CAMPHOR, MENTHOL, MENTHOL, CAMPHOR.
There are a combined 69 reports of application site vesicles across 3 Chattem Inc drug(s) in the FDA adverse event database.